The transjugular intrahepatic portosystemic shunt (TIPS);Der transjugulare intrahepatische portosystemische shunt (TIPS)

Wiener Klinische Wochenschrift

Volumn 112, Issue 22, 2000, Pages 947-954

  Peck Radosavljevic, M ^a   Pidlich, J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ascites; Cirrhosis; Portal hypertension TIPS; Variceal hemorrhage

Indexed keywords

ASCITES; BLOOD PRESSURE REGULATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; HUMAN; LIVER FAILURE; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; RESTENOSIS; REVIEW; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; DRUG CONTRAINDICATION; EQUIPMENT; REOPERATION;

EQUIPMENT FAILURE; HUMANS; HYPERTENSION, PORTAL; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; POSTOPERATIVE COMPLICATIONS; REOPERATION;

EID: 0034711536     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): State of the art
2. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding
3. Transjugular intrahepatic portal-systemic shunts: The state of the art
4. Transjugular intrahepatic portosystemic shunt (TIPS). Thrombogenicity in stents and its effect on shunt patency
5. Surgical treatment of portal hypertension and its sequelae
6. Guidelines for indications of shunt surgery in patients with cirrhosis
7. Controversies in the management of bleeding esophageal varices (2)
8. The surgeon's role in the management of portal hypertension
9. Controversies in the management of bleeding esophageal varices (1)
10. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial
11. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis
12. TIPS for prevention of recurrent bleeding in patients with cirrhosis: Meta-analysis of randomized clinical trials
13. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage
14. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club
15. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites
16. Refractory ascites: Midterm results of treatment with a transjugular intrahepatic portosystemic shunt
17. Transjugular intrahepatic portacaval stent shunts in patients with renal insufficiency
18. Transjugular intrahepatic portosystemic shunts: Comparison with paracentesis in patients with cirrhosis and refractory ascites: A randomized trial
19. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites
20. The role of transjugular portosystemic shunting in patients with ascites
21. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome
22. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems
23. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt
24. Hepatopulmonary syndrome
25. Hepato-pulmonary syndrome: Successful treatment by transjugular intrahepatic portosystemic stent-shunt (TIPS)
26. Transjugular intrahepatic portosystemic shunt improves 6xygenation in hepatopulmonary syndrome
27. Lack of efficacy of TIPS for hepatopulmonary syndrome
28. Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial
29. Duplex ultrasonography and TIPS
30. TIPS: Incidence of shunt-insufficiency: 10 year experience in 1000 patients
31. Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: A randomized trial
32. Acetylsalicylic acid in the prevention of early stenosis and occlu sion of transjugular intrahepatic portal-systemic stent shunts: A controlled study
33. Endothelial cells lining transjugular intrahepatic portasystemic shunts originate in hepatic sinusoids: Implications for pseudointimal hyperplasia
34. Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: A randomized study comparing trapidil plus ticlopidine with heparin treatment
35. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebocontrolled, double-blind study
36. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: Results of a placebo-controlled double-blind study
37. Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting
38. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts
39. Prothrombin time in liver failure: Time, ratio, activity percentage, or international normalized ratio?
40. Transjugular intrahepatic portosystemic shunt: Short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis
41. Transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites: Effect on body weight and Child-Pugh score
42. Improved body composition after TIPS in patients with liver cirrhosis
43. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage
44. A random ized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices
45. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding
46. Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding
47. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: A randomized multicenter trial
48. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters
49. Transjugular intrahepatic portosystemic shunts for refractory ascites: Assessment of clinical and hormonal response and renal function
50. Severe ascites: Efficacy of the transjugular intrahepatic, portosystemic shunt in treatment
51. Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): A caution
52. The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt
53. Atrial natriuretic factor after transjugular intrahepatic portosystemic shunt in liver cirrhosis and ascites